Search

CN-122005615-A - Application of ZM4 of zymomonas mobilis in improving diabetes

CN122005615ACN 122005615 ACN122005615 ACN 122005615ACN-122005615-A

Abstract

The application relates to the technical field of microorganisms, in particular to application of ZM4 in diabetes improvement, which comprises the steps of obtaining a bacterial suspension from ZM4 with the deposit number of ATCC31821 through liquid culture, centrifugation and resuspension, and then using the bacterial suspension in diabetes improvement, wherein ZM4 in the bacterial suspension still has activity after centrifugation and resuspension, and the bacterial suspension does not contain fermentation products of ZM 4. The application of the ZM4 of the zymomonas mobilis in improving diabetes provided by the application utilizes the probiotic characteristics of the ZM4 of the zymomonas mobilis to improve the type and abundance of intestinal flora, so that the blood sugar of a mouse with type II diabetes is reduced, the oral glucose tolerance of the mouse is improved, the contents of glycosylated hemoglobin, blood insulin and GLP-1 are regulated, the level of inflammatory factors related to diabetes is reduced, and damaged islet cells can be improved and recovered to a certain extent.

Inventors

  • HE MINGXIONG
  • WU BO
  • LI JIANTING

Assignees

  • 农业农村部成都沼气科学研究所

Dates

Publication Date
20260512
Application Date
20251225

Claims (8)

  1. 1. The application of ZM4 of zymomonas mobilis in improving diabetes is characterized in that, comprises subjecting ZM4 of Zymomonas mobilis with deposit number ATCC31821 to liquid culture, centrifuging and re-suspending to obtain bacterial suspension, and then using the bacterial suspension for improving diabetes; wherein, the zymomonas mobilis ZM4 in the bacterial suspension still has activity after centrifugation and resuspension; the bacterial suspension does not contain the fermentation product of the zymomonas mobilis ZM 4.
  2. 2. The use according to claim 1, wherein the specific preparation of the bacterial suspension comprises the steps of: Coating the preserved ZM4 of the zymomonas mobilis on a solid culture medium in a streaking way, then culturing at constant temperature, picking single bacterial colonies from a flat plate, inoculating the single bacterial colonies into an RM liquid culture medium, and continuously performing two-generation activation culture to obtain an activated bacterial liquid; inoculating the activated bacterial liquid into an RM liquid culture medium according to an inoculation proportion of 4%, and performing expansion culture to obtain an expansion bacterial liquid; Centrifuging the expanded bacterial liquid, collecting bacterial bodies, washing and re-suspending, and regulating the concentration of the bacterial liquid to obtain the bacterial suspension.
  3. 3. The use according to claim 2, wherein the concentration of the bacterial suspension is 10 9 ~10 10 CFU/mL.
  4. 4. The use according to claim 2, wherein the solid medium comprises RM solid medium; And/or, the liquid medium comprises RM liquid medium.
  5. 5. The use according to claim 2, wherein the washed wash solution is a PBS buffer; and/or, the resuspension is PBS buffer solution.
  6. 6. The use according to claim 2, wherein the temperature of the constant temperature culture is 30±2 ℃, and the time of the constant temperature culture is 2 to 3 d; and/or the temperature of the activation culture is 30 ℃, and the time of the activation culture is 16 h; and/or the temperature of the expansion culture is 30 ℃, and the time of the expansion culture is 16 h; And/or the temperature of the centrifugation is 4 ℃, the speed of the centrifugation is 9000 r/min, and the time of the centrifugation is 10 min.
  7. 7. The use according to any one of claims 1 to 6 for the preparation of a probiotic product associated with diabetes, comprising the preparation of a probiotic product from said bacterial suspension.
  8. 8. The use according to claim 7, wherein the probiotic product comprises a probiotic oral liquid.

Description

Application of ZM4 of zymomonas mobilis in improving diabetes Technical Field The application relates to the technical field of microorganisms, in particular to application of zymomonas mobilis ZM4 in improving diabetes. Background With the rise of living standard, the incidence of diabetes is rapidly increasing due to long-term high-sugar and high-fat eating habits and lack of exercise. Hyperglycemia has been reported by the World Health Organization (WHO) as the third leading risk factor for death, and type II diabetes caused by high blood glucose levels has not only increased incidence but also a trend toward more and more younger. Epidemiological statistics have shown that by 2025, the total number of adult diabetics in China is nearly 1.5 hundred million, diabetes increases the risk of myocardial infarction, stroke and complications related to poor blood circulation of patients, and causes long-term health problems including blindness, cardiovascular diseases, renal failure, amputation, nerve injury and the like. Diabetes is a problem in our country and even worldwide, and various methods have been sought to prevent and improve diabetes, including the treatment of type II diabetes with probiotics. Probiotics are microorganisms which can improve the balance of intestinal flora under the condition of taking a certain amount, have the capabilities of improving intestinal inflammation, inhibiting pathogenic bacteria growth and regulating the immune system of a host, and at present, the relatively common intestinal flora beneficial to the host is mainly lactobacillus and bifidobacterium. The research shows that supplementing the beneficial bacteria can change the intestinal microbial structure, increase the abundance of the beneficial bacteria, inhibit harmful bacteria and conditional pathogenic bacteria, and effectively prevent and treat metabolic diseases such as type II diabetes. The zymomonas mobilis (Zymomonas mobilis) belongs to gram-negative bacteria, is a facultative anaerobic bacterium, is the only bacterium capable of converting glucose and fructose into ethanol through an ED metabolic pathway, and is an important strain for industrial production of ethanol. Furthermore, zymomonas mobilis has also good application in the food industry, and Yang Yongfu et al have shown that it can be used as an alternative strain for yeast, thereby preventing Crohn's disease due to yeast. In addition, zymomonas mobilis also has certain probiotic characteristics, and DE-AZEREDO G A et al evaluate the probiotic characteristics and biosafety of Zymomonas mobilis UFPEDA-202 through rat model experiments, and the results indicate that Zymomonas mobilis is a safe use strain without pathogenicity. However, the current use of Z.mobilis in diabetes generally uses its fermentation under different substrates to produce active substances (e.g., fructooligosaccharides, sorbitol, 3-hydroxybutyric acid, etc.) with therapeutic or palliative effects on diabetes, rather than the probiotic properties of the strain itself. Furthermore, DE AGUIAR S A T et al carried out intestinal tract promoting function and blood lipid level tests on the Zymomonas mobilis isolated from the sugarcane fermentation broth, respectively, and showed that the effect of the sterile fermentation broth was better than that of the probiotic of the bacterial fermentation broth. However, no research has emerged on improving diabetes mellitus using the probiotic properties of zymomonas mobilis. Therefore, further research on zymomonas mobilis is needed to solve the technical blank of improving diabetes by utilizing the probiotic characteristics of zymomonas mobilis at present. Disclosure of Invention The application aims to solve the problems of providing application of ZM4 of zymomonas mobilis in improving diabetes, improving the type and abundance of intestinal flora by utilizing the probiotic characteristics of ZM4 of zymomonas mobilis, thereby reducing the blood sugar of mice with type II diabetes, improving the oral glucose tolerance of the mice, adjusting the contents of glycosylated hemoglobin, blood insulin and GLP-1, reducing the level of inflammatory factors related to diabetes, and improving and recovering damaged islet cells to a certain extent. In order to solve the technical problems, the application adopts the following technical scheme: in one aspect, the application provides the use of ZM4 of ZM for improving diabetes, comprising subjecting ZM4 of ZM with accession number ATCC31821 to liquid culture, centrifugation and resuspension to obtain a bacterial suspension, and then using the bacterial suspension for improving diabetes. After centrifugation and resuspension, the zymomonas mobilis ZM4 in the bacterial suspension still has activity, and the bacterial suspension does not contain a fermentation product of the zymomonas mobilis ZM4, so that the type and abundance of intestinal flora can be improved, the production of short-chain fatty acid is i